Abbott
FDA Approves Abbott's XIENCE V Drug Eluting Stent
Published in Surgery Litigation and Law Weekly, July 18th, 2008
Abbott announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. XIENCE V is the only drug eluting stent to have demonstrated superiority over Boston Scientific's TAXUS(R) paclitaxel-eluting coronary stent system in two randomized head-to-head clinical trials. XIENCE V will be launched in the United States immediately.
"XIENCE V represents an important treatment advance for the estimated 13 million people in the United States suffering from coronary artery disease, and we believe XIENCE V will quickly become the new standard for drug eluting stents given its...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly
More Articles from Surgery Litigation and Law Weekly
- Autopsy
Data from University of Hamburg advance knowledge in autopsy - Health Discovery Corporation
Health Discovery Corporation Announces Successful Phase II Clinical Trial Results for New Gene-Based Molecular Diagnostic Test for Prostate Cancer - Merck & Co., Inc.
Merck & Co., Inc Receives Complete Response Letter from the Food and Drug Administration for Use of GARDASIL in Women Ages 27 through 45 - Abdominal Aortic Aneurysm
Studies from J.B. Dimick and colleagues reveal new findings on abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Study data from University of Copenhagen update understanding of abdominal aortic aneurysm - Abdominal Aortic Aneurysm
Surgeons Role in Abdominal Aortic Aneurysms Mortality Examined - More from this issue of Surgery Litigation and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
